Glaukos Corp Company Profile (NYSE:GKOS)

Glaukos Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos Corp (NYSE:GKOS) posted its quarterly earnings data on Wednesday, March, 1st. The company reported $0.00 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.00 by $0.00. The firm had revenue of $33.17 million for the quarter, compared to analysts' expectations of $29.49 million. Glaukos Corp had a net margin of 2.07% and a return on equity of 2.05%. The business's quarterly revenue was up 63.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.07) EPS. View Glaukos Corp's Earnings History.

7 brokerages have issued twelve-month price objectives for Glaukos Corp's stock. Their forecasts range from $41.00 to $55.00. On average, they anticipate Glaukos Corp's stock price to reach $49.20 in the next twelve months. View Analyst Ratings for Glaukos Corp.

Here are some recent quotes from research analysts about Glaukos Corp stock:

• 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (5/2/2017)
• 2. Cantor Fitzgerald analysts commented, "We are reiterating our Overweight rating on GKOS and raising our price target to $54 from $45, following what we view as impressive 4Q16 results and strong revenue guidance for 2017. Yesterday after the close, Glaukos reported 4Q16 revenues of $33.2 million, beating our revenue estimate of $30.0 million. We note that $2 million of the growth was associated with advanced sales to ASC customers ahead of increased reimbursement changes. Management provided initial 2017 sales guidance of $160-165 million, above our previous estimate of $140 million. We have updated our model to reflect the better-than-anticipated guidance and are extending our NPV out by one year, which is reflected in our increased 12-month price target." (3/2/2017)
• 3. Stifel Nicolaus analysts commented, "Glaukos' stock has considerably outperformed the market YTD (+29% relative to the S&P). We attribute the strong performance to ongoing positive investor sentiment as well as a better understanding of the pricing power that the company possesses in 2017 due to the favorable Ambulatory Surgical Center (ASC) reimbursement decision that took hold at the beginning of the year. While Glaukos does not plan to provide ASP details, our late January diligence among a small number of iStent physicians unveiled that Glaukos is in the midst of implementing a significant price increase (~40%) among iStent cases performed at the ASC. A price increase of this magnitude implies upside to the Street's current 2017 revenue estimate of $147.5MM (we are at $151.4MME), and our January report laid out a case where 2017 revenue could total $180MM+. As investors have better understood the power of price over the past few weeks, we believe the bar has been raised into the company's 2017 guidance, which will be provided on Wednesday (AMC). In this report, we take a near-term look at what different 2017 revenue guidance levels imply for 2017 iStent volumes based on our ASP diligence. We also take a longer-term look at Glaukos' future earnings power, which we view as significant, and believe will become more evident in 2H17 / 1H18. Simply put, we can see 2019 adjusted EBITDA per share (which we use as a proxy for cash EPS) of $2.23 to $3.33, which does not include future pipeline products such as iDose, or the significant market opportunity associated with the stand-alone Glaucoma market." (2/28/2017)

Some companies that are related to Glaukos Corp include Insulet (PODD), Haemonetics (HAE), Inogen (INGN), Merit Medical Systems (MMSI), Halyard Health (HYH), Mazor Robotics Ltd - (MZOR), Luminex (LMNX), OraSure Technologies (OSUR), AtriCure (ATRC), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), Endologix (ELGX), Antares Pharma (ATRS), STAAR Surgical Company (STAA), Entellus Medical (ENTL), ConforMIS (CFMS), Sientra (SIEN) and Invuity (IVTY).

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos Corp's stock is owned by many different of retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (6.03%), Janus Capital Management LLC (5.15%), Vanguard Group Inc. (4.71%), Gilder Gagnon Howe & Co. LLC (4.37%), Alliancebernstein L.P. (3.77%) and Renaissance Technologies LLC (3.52%). Company insiders that own Glaukos Corp stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos Corp.

Glaukos Corp's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Next Century Growth Investors LLC, Cortina Asset Management LLC, Wellington Management Group LLP, JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp DE and Hamilton Lane Advisors LLC. Company insiders that have sold Glaukos Corp stock in the last year include Chris M Calcaterra, Jonathan Silverstein, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos Corp.

Glaukos Corp's stock was purchased by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Wells Fargo & Company MN, Alliancebernstein L.P., Renaissance Technologies LLC, Vanguard Group Inc., OppenheimerFunds Inc., FMR LLC and Driehaus Capital Management LLC. Company insiders that have bought Glaukos Corp stock in the last two years include Aimee S Weisner and Richard L Harrison. View Insider Buying and Selling for Glaukos Corp.

Shares of Glaukos Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Glaukos Corp stock can currently be purchased for approximately $39.01.